Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06163170 · ClinicalTrials.gov registry record
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 100
- Enrollment target
NCT06163170 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 100 participants.
The verdict
NCT06163170 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to describe real-world safety outcomes in children with melanoma who are treated with nivolumab alone or nivolumab in combination with ipilimumab for unresectable or metastatic melanoma, or treated with adjuvant nivolumab after resection of stage IIB-IV melanoma. Demographic and clinical characteristics, and treatment patterns, will also be described in this population.
Interventions
- DRUG Nivolumab
- DRUG Nivolumab +/- ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-08-14 |
| Est. Completion | 2023-11-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06163170
The ClinicalTrials.gov registry entry for NCT06163170 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT06163170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06163170 about?
NCT06163170 is a clinical study titled "A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma". The purpose of this study is to describe real-world safety outcomes in children with melanoma who are treated with nivolumab alone or nivolumab in combination with ipilimumab for unresectable or metastatic melanoma, or treated with adjuvant nivolumab after resection of stage IIB-IV melanoma. Demogra...
What is the current status of trial NCT06163170?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2023-08-14. Estimated completion is 2023-11-10.
What interventions are being tested in trial NCT06163170?
The interventions under investigation include: Nivolumab (DRUG), Nivolumab +/- ipilimumab (DRUG).
Who is sponsoring clinical trial NCT06163170?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.